Cytogenetic profiles as additional markers to pathological features in clinically localized prostate carcinoma

被引:15
作者
Gallucci, Michele
Merola, Roberta
Farsetti, Antonella
Orlandi, Giulia
Sentinelli, Steno
De Carli, Piero
Leonardo, Costantino
Carlini, Paolo
Guadagni, Fiorella
Sperduti, Isabella
Cianciulli, Anna Maria
机构
[1] Regina Elena Inst Canc Res, Dept Clin Pathol, IFO, Cytogenet Unit, I-00144 Rome, Italy
[2] Regina Elena Inst Canc Res, DepUro, Rome, Italy
[3] CNR, Inst Neurobiol & Mol Med, Rome, Italy
[4] Regina Elena Inst Canc Res, Dept Pathol, Rome, Italy
[5] Regina Elena Inst Canc Res, Dept Oncol, Rome, Italy
[6] Regina Elena Inst Canc Res, Biostat Unit, Rome, Italy
关键词
genetic markers; prostate cancer; FISH;
D O I
10.1016/j.canlet.2005.05.033
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Fluorescence in situ hybridization analysis for evaluation of 7, 8, X chromosomes and EGFR, LPL, MYC, AR genes in 79 neoplastic foci from 56 patients with clinically localized prostate cancer was performed. We found aneusomy for chromosome 7, 8 and X in 74/77 (96.1%), 56/76 (73.7%), 26/70 (37.1%) of examined foci respectively. No specimen was amplified for EGFR and AR genes, only 2/71 (2.8%) specimens showed MYC gene amplified. LPL deletion was present in 52/76 (68.4%) specimens. Statistically association between Gleason score and both chromosome 7 aneusomy and 8p21 deletion was present. The frequency of chromosome 7 aneusomy was statistically higher in T3-4 cases than T2c and T2a-T2b ones. We considered as unfavorable a genetic set if aneusomy for at least two chromosomes and one altered gene were present. The percentage of tumors, with unfavorable genetic pattern, increased from 36.4 to 75.0% in those with Gleason > 7 and from 40.0 to 73.7% in those with stage T3 or more. These alterations could be considered potent genetic markers adjunctive to conventional prognostic parameters. Our objective was to establish specific genetic profiles which may discriminate favorable and unfavorable genetic prognosis tumors. (c) 2005 Elsevier Ireland Ltd. All fights reserved.
引用
收藏
页码:76 / 82
页数:7
相关论文
共 24 条
[1]   Molecular genetics of prostate cancer [J].
Abate-Shen, C ;
Shen, MM .
GENES & DEVELOPMENT, 2000, 14 (19) :2410-2434
[2]   Identification of genetic markers for prostatic cancer progression [J].
Alers, JC ;
Rochat, J ;
Krijtenburg, PJ ;
Hop, WCJ ;
Kranse, R ;
Rosenberg, C ;
Tanke, HJ ;
Schröder, FH ;
van Dekken, H .
LABORATORY INVESTIGATION, 2000, 80 (06) :931-942
[3]   Molecular cytogenetic analysis of prostatic adenocarcinomas from screening studies -: Early cancers may contain aggressive genetic features [J].
Alers, JC ;
Krijtenburg, PJ ;
Vis, AN ;
Hoedemaeker, RF ;
Wildhagen, MF ;
Hop, WCJ ;
van der Kwast, TH ;
Schröder, FH ;
Tanke, HJ ;
van Dekken, H .
AMERICAN JOURNAL OF PATHOLOGY, 2001, 158 (02) :399-406
[4]  
Amati B., 1998, FRONT BIOSCI, V3, pd250, DOI DOI 10.2741/A239
[5]  
Bostwick DG, 1998, CANCER, V83, P1995, DOI 10.1002/(SICI)1097-0142(19981101)83:9<1995::AID-CNCR16>3.0.CO
[6]  
2-2
[7]  
Cairns P, 1997, CANCER RES, V57, P4997
[8]   Genetic instability in superficial bladder cancer and adjacent mucosa: An interphase cytogenetic study [J].
Cianciulli, AM ;
Leonardo, C ;
Guadagni, F ;
Marzano, R ;
Iori, F ;
De Nunzio, C ;
Franco, G ;
Merola, R ;
Laurenti, C .
HUMAN PATHOLOGY, 2003, 34 (03) :214-221
[9]  
Di Lorenzo G, 2002, CLIN CANCER RES, V8, P3438
[10]   Molecular genetics of prostate cancer [J].
Elo, JP ;
Visakorpi, T .
ANNALS OF MEDICINE, 2001, 33 (02) :130-141